Last reviewed · How we verify
NCT05111795: RECORD
Holmium-166 Retrospective Collection of Real-World Data
trial testing Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres in Hepatocellular Carcinoma in 146 participants. Completed in 8 April 2022.
15 February 2022
Quick facts
| Lead sponsor | Terumo Europe N.V. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 146 |
| Start date | 17 January 2022 |
| Primary completion | 15 February 2022 |
| Estimated completion | 8 April 2022 |
| Sites | 12 locations across Italy, Netherlands, Belgium, Germany, Switzerland, Portugal, Spain |
Drugs / interventions tested
- Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres
Conditions studied
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
- Metastatic Cancer — all drugs for Metastatic Cancer →
Sponsor
Terumo Europe N.V.
Who can join
18 and older, any sex, with Hepatocellular Carcinoma or Metastatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of the study is to further describe the general safety and clinical performance of QuiremSpheresTM Holmium-166 Microspheres and QuiremScoutTM Holmium-166 Microspheres in a real-world post-market setting, with specific attention to outcomes per tumor origin.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Holmium-166 Radioembolization: Current Status and Future Prospective.
Stella M, Braat AJAT, van Rooij R, de Jong HWAM, et al · · 2022 · cited 40× · PMID 35729423 · DOI 10.1007/s00270-022-03187-y
Verify or expand the search:
- PubMed search for NCT05111795
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
- NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
- NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting
Other Terumo Europe N.V. trials
Trials by the same sponsor.
- NCT05911633 — BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC) · NA · recruiting
- NCT05451862 — Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma. · NA · terminated
- NCT05705973 — Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients · active not recruiting
- NCT05027698 — Post-Market Clinical Investigation of the FemoSeal™ VCS: A Prospective, Multi-Center Observational European Study · completed
- NCT04546477 — Prospective Multicenter Study to Confirm the Performance of the Renzan Stent in Treatment of SFA/POP Artery Disease · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05111795 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Terumo Europe N.V.
- Last refreshed: 30 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05111795.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing